Match tier
Listed
Presence
Current · Arkansas
Last published
2024
Sources
OpenAlex · ORCID
Refreshed
2026-10-03
Jeffery R. Sawyer
Professor
Also affiliated: Arkansas Children's Hospital (1994–2008); University of Minnesota (2008); University of Arkansas Medical Center (2023); Cancer Research And Biostatistics (2009); Erasmus MC Cancer Institute (2019); University of Oklahoma Health Sciences Center (2005)
Pathology, College of Medicine
8 h-index
39 pubs
571 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Jeffery R. Sawyer's research focuses on the cytogenetic and molecular underpinnings of multiple myeloma, a cancer of plasma cells. His work investigates how specific chromosomal abnormalities, such as the deletion of chromosome 1p13.3 and the amplification or gain of chromosome 1q21, correlate with patient outcomes. He has published findings demonstrating that the concomitant presence of these two alterations is associated with a poorer prognosis in multiple myeloma patients, utilizing fluorescence in situ hybridization (FISH) for detection. Additionally, Sawyer's research has explored the role of phenotypic markers identified through eight-color flow cytometry in predicting disease progression in monoclonal gammopathy of unknown significance, a precursor condition to multiple myeloma. His scholarship metrics include an h-index of 10 and 55 total publications, with 670 citations.
Metrics
- h-index: 8
- Publications: 39
- Citations: 571
Positions
-
Professor publications 1994–2024University of Arkansas for Medical Sciences Pathology, College of Medicine Institutional directory
Selected Publications
-
Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes (2024)
-
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma (2023)
-
Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome (2021)
-
Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance (2021)
-
Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups (2019)
-
The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells (2019)
-
EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab (2019)
-
An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome (2018)
-
Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53 (2018)
-
Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma (2017)
-
Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status (2017)
-
Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC (2016)
-
Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression (2016)
-
Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma (2015)
-
A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant (2015)
Grants & Funding
As listed on this researcher's institutional profile.
- DNA Hypomethylation and Cancer NIH/Nat. Cancer Institute Principal Investigator
Collaboration Network
Top Collaborators
Frits van Rhee
Winthrop Rockefeller Foundation
18 shared publications
In database
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
- Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53
Showing 5 of 18 shared publications
Maurizio Zangari
Winthrop Rockefeller Foundation
18 shared publications
In database
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
- Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53
Showing 5 of 18 shared publications
Carolina Schinke
Winthrop Rockefeller Foundation
15 shared publications
In database
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
- Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53
- A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant
Showing 5 of 15 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
14 shared publications
In database
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
- Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53
- A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant
Showing 5 of 14 shared publications
Gareth John Morgan
University of Arkansas for Medical Sciences (US)
12 shared publications
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
- Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53
- A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant
Showing 5 of 12 shared publications
Faith E. Davies
University of Arkansas for Medical Sciences (US)
11 shared publications
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
- Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53
- A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant
Showing 5 of 11 shared publications
Erming Tian
Winthrop Rockefeller Foundation
10 shared publications
In database
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression
- Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Showing 5 of 10 shared publications
Bart Barlogie
Icahn School of Medicine at Mount Sinai
9 shared publications
In database
- Malignant pleural effusion of multiple myeloma: Prognostic factors and outcome
- Clinical, Immunophenotypic, and Genetic Characterization of Small Lymphocyte–Like Plasma Cell Myeloma
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
- A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant
- Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups
Showing 5 of 9 shared publications
Brian A. Walker
University of Arkansas for Medical Sciences (US)
7 shared publications
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
- Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53
- Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression
- Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC
Showing 5 of 7 shared publications
Guido J. K. Tricot
Winthrop Rockefeller Foundation
5 shared publications
In database
- Malignant pleural effusion of multiple myeloma: Prognostic factors and outcome
- Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
- MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.
- Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome
Meera Mohan
Medical College of Wisconsin (US)
5 shared publications
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
- Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status
- Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome
Clyde Bailey
University of Arkansas for Medical Sciences
5 shared publications
In database
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
- A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant
- Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma
Gael Sammartino
University of Arkansas for Medical Sciences
4 shared publications
In database
- Clonal chromosome aberrations in a case of nodular fasciitis
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC
- Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma
Fenghuang Zhan
Winthrop Rockefeller Foundation
4 shared publications
In database
- Clinical, Immunophenotypic, and Genetic Characterization of Small Lymphocyte–Like Plasma Cell Myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
- Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome
John D. Shaughnessy
Winthrop Rockefeller Foundation
4 shared publications
In database
- Clinical, Immunophenotypic, and Genetic Characterization of Small Lymphocyte–Like Plasma Cell Myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Benefit of thalidomide (THAL) in total therapy 2 (TT2) of multiple myeloma (MM) exhibiting both cytogenetic abnormalities (CA) and low-risk (LR) by gene expression profiling (GEP)
- MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.
Similar Researchers
Based on overlapping research topics
Riley K Russo
University of Arkansas at Fayetteville
Cancer-related molecular mechanisms research
Retrospective Studies
Medical Case Studies
KK Zorn
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Retrospective Studies
Medical Case Studies
A Al Kharabsheh
Harding University Main Campus
Cancer-related molecular mechanisms research
Retrospective Studies
Medical Case Studies
S. Mehdi
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders
Medical Case Studies
Donald Bodenner
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders
Retrospective Studies
Janet L. Lukacs
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders